Year None2024202320222021 April 2, 2024 Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million February 13, 2024 Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update January 30, 2024 Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
April 2, 2024 Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
February 13, 2024 Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
January 30, 2024 Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024